- DetermaIO is a novel tumor microenvironment classifier that measures expression levels of 27 genes and predicts response to immune checkpoint inhibitor therapies in multiple cancer types.
- Two separate validation studies have shown the association with response to checkpoint inhibitor therapy in non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC).
- More than half of eligible cancer patients put on immune therapy every year do not respond.
Register HERE or click the button on the Right.
Up to 750,000 patients may be eligible for immunotherapy each year, yet today more than half of patients treated with immunotherapy won't respond. There continues to be a critical unmet need for a predictive biomarker that can identify responders and non-responders at diagnosis.
DetermaIO is a novel test that measures expression of 27 genes from the tumor microenvironment and uses a proprietary algorithm to predict response to immunotherapies.
In this webinar, we will present results from two studies showing the association of DetermaIO with response to checkpoint inhibitor therapy in non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). Both studies suggest that DetermaIO outperformed PD-L1 and/or TMB in predicting immunotherapy response. The studies were led by multiple leading academic institutions, including the University of Texas MD Anderson Cancer Center, Yale University, the Baylor College of Medicine, and the University of Tennessee Health Science Center.
Dr. Naoto Ueno will discuss results from an MD Anderson/Yale study that were presented at this year's virtual ASCO meeting in TNBC.
Dr. Doug Ross will discuss previously reported results in NSCLC that showed DetermaIO's improved ability to predict response to immunotherapies over current leading biomarkers (PD-L1 expression & TMB).
Register in advance HERE
Triple Negative Breast Cancer/Immunotherapy in TNBC:
- Triple Negative Breast Cancer accounts for 15-20% of all breast cancer cases and is defined by the absence of three common genetic markers: Estrogen Receptor (ER), Progesteron Receptor (PR), and HER2.
- TNBC tumors tend to be more aggressive with poorer prognosis than other breast cancer tumors, and few options for targeted therapy exist for this patient population.
- At present, a single immunotherapy has been approved for metastatic PD-L1+ TNBC, however a number of other IO drugs are being studied in a number of different clinical trials to offer additional therapeutic options for TNBC patients